Related references
Note: Only part of the references are listed.Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer
N. C. Turner et al.
ANNALS OF ONCOLOGY (2023)
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
Qing Zhou et al.
CLINICAL CANCER RESEARCH (2022)
Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer
Yanbo Li et al.
EUROPEAN RADIOLOGY (2022)
Deep cfDNA fragment end profiling enables cancer detection
Yulia V. Zhitnyuk et al.
MOLECULAR CANCER (2022)
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
Aleix Prat et al.
EBIOMEDICINE (2022)
Role of ctDNA in Breast Cancer
Marta Sant et al.
CANCERS (2022)
Breast Cancer; Discovery of Novel Diagnostic Biomarkers, Drug Resistance, and Therapeutic Implications
Samia Afzal et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2022)
Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review
Nhu Hanh To et al.
BREAST CANCER RESEARCH AND TREATMENT (2022)
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis
Andri Papakonstantinou et al.
CANCER TREATMENT REVIEWS (2022)
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy
Mark Jesus M. Magbanua et al.
FRONTIERS IN ONCOLOGY (2022)
Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer
Adriaan Vanderstichele et al.
NPJ GENOMIC MEDICINE (2022)
Cell-Free DNA Fragmentomics in Liquid Biopsy
Spencer C. Ding et al.
DIAGNOSTICS (2022)
Anthracyclines in the treatment of patients with early breast cancer
V Guarneri et al.
ESMO OPEN (2022)
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer
Caterina Gianni et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
J. Pascual et al.
ANNALS OF ONCOLOGY (2022)
ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis
Mikail Gogenur et al.
ANNALS OF SURGICAL ONCOLOGY (2022)
miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis
Zhuo Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2022)
Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers
Sridevi Addanki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Small Non-Coding RNAs in Human Cancer
Qunli Xiong et al.
GENES (2022)
Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer
Ruo-Kai Lin et al.
MOLECULAR MEDICINE (2022)
Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells
Timothy Crook et al.
CANCERS (2022)
In Early Breast Cancer, the Ratios of Neutrophils, Platelets and Monocytes to Lymphocytes Significantly Correlate with the Presence of Subsets of Circulating Tumor Cells but Not with Disseminated Tumor Cells
Sabine Kasimir-Bauer et al.
CANCERS (2022)
The Early Detection of Breast Cancer Using Liquid Biopsies: Model Estimates of the Benefits, Harms, and Costs
Esmee K. J. van der Poort et al.
CANCERS (2022)
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis
Tania Rossi et al.
CANCERS (2022)
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment
Caterina Gianni et al.
FRONTIERS IN ONCOLOGY (2022)
Infrared molecular fingerprinting: A new in vitro diagnostic platform technology for cancer detection in blood-based liquid biopsies
M. Zigman et al.
ANNALS OF ONCOLOGY (2022)
A prospective study of a multi-cancer early detection blood test
D. Schrag et al.
ANNALS OF ONCOLOGY (2022)
A multi-cancer early detection model based on liquid biopsy of multi-omics biomarkers: A proof of concept study (PROMISE study)
Q. Gao et al.
ANNALS OF ONCOLOGY (2022)
Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
Renata Colombo Bonadio et al.
CANCER TREATMENT REVIEWS (2022)
Comprehensive characterization of RNA cargo of extracellular vesicles in breast cancer patients undergoing neoadjuvant chemotherapy
Lilite Sadovska et al.
FRONTIERS IN ONCOLOGY (2022)
Graphene Oxide-Based Highly Sensitive Assay of Circulating MicroRNAs for Early Prediction of the Response to Neoadjuvant Chemotherapy in Breast Cancer
Zhijia Li et al.
ANALYTICAL CHEMISTRY (2022)
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse
Frederic Cailleux et al.
JCO PRECISION ONCOLOGY (2022)
The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy
Lorena Alexandra Lisencu et al.
MEDICINA-LITHUANIA (2022)
DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival
Christine Aaserod Pedersen et al.
BREAST CANCER RESEARCH (2022)
Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter?
Dinara Ryspayeva et al.
DISCOVER ONCOLOGY (2022)
Liquid Biopsy in Breast Cancer
Timothy Kwang Yong Tay et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2021)
Can We Reliably Identify the Pathological Outcomes of Neoadjuvant Chemotherapy in Patients with Breast Cancer? Development and Validation of a Logistic Regression Nomogram Based on Preoperative Factors
Jian Zhang et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+subtype
Satu Tiainen et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Laura Keller et al.
BRITISH JOURNAL OF CANCER (2021)
circRNA-miRNA-mRNA in breast cancer
Meilan Zhang et al.
CLINICA CHIMICA ACTA (2021)
Exosomal miRNA profiles of triple-negative breast cancer in neoadjuvant treatment
Aiko Sueta et al.
ONCOLOGY LETTERS (2021)
Lymphocyte-to-Monocyte Ratio is Associated with the Poor Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Youzhao Ma et al.
CANCER MANAGEMENT AND RESEARCH (2021)
Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer
Zhuo Zhang et al.
THORACIC CANCER (2021)
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis
Fabio Conforti et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Heterogeneity of CTC contributes to the organotropism of breast cancer
Tao Yu et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells
Amir Sadra Zangouei et al.
CANCER CELL INTERNATIONAL (2021)
Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
Arlou Kristina Angeles et al.
CANCERS (2021)
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature
Chrystel Isca et al.
CANCERS (2021)
Preoperative Systemic Inflammatory Biomarkers Are Independent Predictors of Disease Recurrence in ER+HER2-Early Breast Cancer
Marta Truffi et al.
FRONTIERS IN ONCOLOGY (2021)
Factors Affecting Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: Development and Validation of a Predictive Nomogram
Soo-Yeon Kim et al.
RADIOLOGY (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Association between the nucleosome footprint of plasma DNA and neoadjuvant chemotherapy response for breast cancer
Xu Yang et al.
NPJ BREAST CANCER (2021)
How to use liquid biopsies to treat patients with cancer
L. De Mattos-Arruda et al.
ESMO OPEN (2021)
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy
E. Ortolan et al.
ESMO OPEN (2021)
High Cell-Free DNA Integrity Is Associated with Poor Breast Cancer Survival
Maria Lamminaho et al.
Cancers (2021)
Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue
Tania Rossi et al.
BIOMEDICINES (2021)
Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
Irina Palacin-Aliana et al.
BIOMEDICINES (2021)
Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analysis
Qiong Zhou et al.
BMJ OPEN (2021)
Circular RNAs: Potential Applications as Therapeutic Targets and Biomarkers in Breast Cancer
Debina Sarkar et al.
NON-CODING RNA (2021)
Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5 years after diagnosis and late recurrence
Gilseong Moon et al.
BREAST CANCER (2020)
Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients
Yang Peng et al.
CANCER BIOLOGY & THERAPY (2020)
Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer
J. Moss et al.
ANNALS OF ONCOLOGY (2020)
Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2-) Breast Cancer
Yuanping Hu et al.
CLINICAL BREAST CANCER (2020)
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)
Lorenzo Gerratana et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy
Li Chen et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation
Peiyong Jiang et al.
CANCER DISCOVERY (2020)
DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types
Vera Constancio et al.
CELLS (2020)
Inflammation-Based Scores Increase the Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer
Svetlana Miklikova et al.
CANCERS (2020)
Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Breast Cancer: A Propensity Score-Matching Study
Xin Hua et al.
FRONTIERS IN ONCOLOGY (2020)
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M. C. Liu et al.
ANNALS OF ONCOLOGY (2020)
Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
Sarah Talamantes et al.
CANCER MEDICINE (2020)
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial
Milan Radovich et al.
JAMA ONCOLOGY (2020)
Cell Death in the Origin and Treatment of Cancer
Andreas Strasser et al.
MOLECULAR CELL (2020)
Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
Luca Cavallone et al.
SCIENTIFIC REPORTS (2020)
Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Ileana Corbeau et al.
CANCERS (2020)
Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer
Tania Rossi et al.
CANCERS (2020)
Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer A Systematic Review and Meta-analysis
Carolyn Cullinane et al.
JAMA NETWORK OPEN (2020)
Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Serena Di Cosimo et al.
CLINICAL CANCER RESEARCH (2019)
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Francoise Rothe et al.
CLINICAL CANCER RESEARCH (2019)
Neutrophils escort circulating tumour cells to enable cell cycle progression
Barbara Maria Szczerba et al.
NATURE (2019)
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Klaus Pantel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Regional methylome profiling reveals dynamic epigenetic heterogeneity and convergent hypomethylation of stem cell quiescence-associated genes in breast cancer following neoadjuvant chemotherapy
Yumei Luo et al.
CELL AND BIOSCIENCE (2019)
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Begona Pineda et al.
CLINICAL EPIGENETICS (2019)
Genome-wide cell-free DNA fragmentation in patients with cancer
Stephen Cristiano et al.
NATURE (2019)
Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals
Wanying Guo et al.
CANCER MEDICINE (2019)
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
Isaac Garcia-Murillas et al.
JAMA ONCOLOGY (2019)
Never Travel Alone: The Crosstalk of Circulating Tumor Cells and the Blood Microenvironment
Simon Heeke et al.
CELLS (2019)
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
Bradon R. McDonald et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Plasma cell-free DNA integrity: a potential biomarker to monitor the response of breast cancer to neoadjuvant chemotherapy
Wei Wang et al.
TRANSLATIONAL CANCER RESEARCH (2019)
Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA
Ymke van der Pol et al.
CANCER CELL (2019)
Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions
Fabienne Schochter et al.
CELLS (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Circulating Tumor Cells in Early Breast Cancer
Laura Thery et al.
JNCI CANCER SPECTRUM (2019)
The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs
Afsane Bahrami et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial
M. Ignatiadis et al.
ANNALS OF ONCOLOGY (2018)
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Jason D. Merker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Analysis of DNA methylation in cancer: location revisited
Alexander Koch et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Macrophages orchestrate breast cancer early dissemination and metastasis
Nina Linde et al.
NATURE COMMUNICATIONS (2018)
Prognostic Significance of Neutrophil-to-lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer
Patrizia Ferroni et al.
ANTICANCER RESEARCH (2018)
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
Ines Stevic et al.
BMC MEDICINE (2018)
Circulating circular RNA hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection
Wei-Bing Yin et al.
CLINICA CHIMICA ACTA (2018)
Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives?
Navid Sobhani et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2018)
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and-2) of neoadjuvant chemotherapy combined with bevacizumab
J-Y Pierga et al.
ANNALS OF ONCOLOGY (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence
Jie Cheng et al.
ONCOTARGET (2017)
Identification of circular RNAs as a promising new class of diagnostic biomarkers for human breast cancer
Lingshuang Lu et al.
ONCOTARGET (2017)
Methylation patterns in serum DNA for early identification of disseminated breast cancer
Martin Widschwendter et al.
GENOME MEDICINE (2017)
Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer
Peter McAnena et al.
CANCERS (2017)
The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer
Hideya Takeuchi et al.
PLOS ONE (2017)
Awareness and current knowledge of breast cancer
Muhammad Akram et al.
BIOLOGICAL RESEARCH (2017)
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
Yu-Hsiang Chen et al.
NPJ BREAST CANCER (2017)
Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant Geparquattro Trial
Sabine Riethdorf et al.
CLINICAL CANCER RESEARCH (2017)
Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy
J. Xu et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Jonathan C. M. Wan et al.
NATURE REVIEWS CANCER (2017)
Patient -Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple -Negative Breast Cancer
Francesca Riva et al.
CLINICAL CHEMISTRY (2017)
Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer
Azza M. Kamel et al.
TUMOR BIOLOGY (2016)
Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin
Matthew W. Snyder et al.
CELL (2016)
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Wolfgang J. Janni et al.
CLINICAL CANCER RESEARCH (2016)
Androgen receptor signaling pathways as a target for breast cancer treatment
Elisabetta Pietri et al.
ENDOCRINE-RELATED CANCER (2016)
Study of microRNAs-21/221 as potential breast cancer biomarkers in Egyptian women
Tarek Mohamed Kamal Motawi et al.
GENE (2016)
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Luca Gianni et al.
LANCET ONCOLOGY (2016)
Nucleosome mapping in plasma DNA predicts cancer gene expression
Muhammed Murtaza et al.
NATURE GENETICS (2016)
Inferring expressed genes by whole-genome sequencing of plasma DNA
Peter Ulz et al.
NATURE GENETICS (2016)
Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer
Seema Thakur et al.
PLOS ONE (2016)
Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer
Carolyn Hall et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer
C-H Koh et al.
BRITISH JOURNAL OF CANCER (2015)
Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay
Hye-young Wang et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
Prognostic Significance of Preoperative Circulating Monocyte Count in Patients With Breast Cancer Based on a Large Cohort Study
Jiahuai Wen et al.
MEDICINE (2015)
Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer
Sobuhi Iqbal et al.
SPRINGERPLUS (2015)
Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data
Jean-Yves Pierga et al.
CLINICAL CANCER RESEARCH (2015)
Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
Wendy Onstenk et al.
MOLECULAR CANCER THERAPEUTICS (2015)
EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer
Helen Schneck et al.
PLOS ONE (2015)
Biological properties of extracellular vesicles and their physiological functions
Maria Yanez-Mo et al.
JOURNAL OF EXTRACELLULAR VESICLES (2015)
MicroRNA expression profiles of serum from patients before and after chemotherapy
Yvonne Diener et al.
GENOMICS DATA (2015)
Circulating tumor cells in newly diagnosed inflammatory breast cancer
Michal Mego et al.
BREAST CANCER RESEARCH (2015)
The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients
S. Krenn-Pilko et al.
BRITISH JOURNAL OF CANCER (2014)
DNAMethylation Status of Key Cell-Cycle Regulators Such as CDKNA2/p16 and CCNA1 Correlates with Treatment Response to Doxorubicin and 5-Fluorouracil in Locally Advanced Breast Tumors
Jovana Klajic et al.
CLINICAL CANCER RESEARCH (2014)
Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy
Hye-Young Wang et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2014)
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
Francois-Clement Bidard et al.
LANCET ONCOLOGY (2014)
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial
Hatem A. Azim et al.
BREAST (2013)
Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin
Oliver J. Stoetzer et al.
CANCER LETTERS (2013)
Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy
Julia Lehner et al.
CLINICA CHIMICA ACTA (2013)
Intercellular Communication by Exosome-Derived microRNAs in Cancer
Bethany N. Hannafon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer
Gary C. Hon et al.
GENOME RESEARCH (2012)
Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system
E. Andreopoulou et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Circulating tumour cells as biomarkers in early breast cancer
Jonathan Krell et al.
LANCET ONCOLOGY (2012)
Circulating tumour cells in non-metastatic breast cancer: a prospective study
Anthony Lucci et al.
LANCET ONCOLOGY (2012)
Landscape of transcription in human cells
Sarah Djebali et al.
NATURE (2012)
Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy
Maria Jose Serrano et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2012)
Cell-free nucleic acids as biomarkers in cancer patients
Heidi Schwarzenbach et al.
NATURE REVIEWS CANCER (2011)
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
Mario Giuliano et al.
BREAST CANCER RESEARCH (2011)
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer
F. -C. Bidard et al.
ANNALS OF ONCOLOGY (2010)
Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
L. M. Flores et al.
BRITISH JOURNAL OF CANCER (2010)
Detection of Minimal Residual Disease in Blood and Bone Marrow in Early Stage Breast Cancer
Savitri Krishnamurthy et al.
CANCER (2010)
Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial
Sabine Riethdorf et al.
CLINICAL CANCER RESEARCH (2010)
18F-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer
Ugo De Giorgi et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Global Histone Modifications in Breast Cancer Correlate with Tumor Phenotypes, Prognostic Factors, and Patient Outcome
Somaia E. Elsheikh et al.
CANCER RESEARCH (2009)
Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression
Junko Suzuki et al.
CLINICAL CANCER RESEARCH (2009)
Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial
Jean-Yves Pierga et al.
CLINICAL CANCER RESEARCH (2008)
CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
Ranjan Chrisanthar et al.
PLOS ONE (2008)
MicroRNA gene expression deregulation in human breast cancer
MV Iorio et al.
CANCER RESEARCH (2005)
Circulating tumor-specific DNA: A marker for monitoring efficacy of adjuvant therapy in cancer patients
H Fiegl et al.
CANCER RESEARCH (2005)
DNA methylation and breast cancer
M Szyf et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
